In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer Hooks Up With Arena In CNS

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim GmbH has agreed to pay up to $262m in milestones to Arena Pharmaceuticals, Inc. under a new R&D agreement. The two will jointly research and develop CNS drugs against an undisclosed G protein-coupled receptor (GPCR) whose ligand has not been identified. Arena will share internally discovered compounds and IP for the CNS receptor, and use technology it has developed to discover drugs targeting GPCRs even when their natural ligand is not known. Such receptors are known as "orphan GPCRs", and being able to analyze these as well as GPCRs with known ligands increases the chances of finding new therapies. BI hopes the alliance with Arena will lead to new treatments for psychiatric diseases such as schizophrenia. The German firm's only marketed CNS drug is Mirapex (pramipexole) for Parkinson's Disease, but it recently extended its R&D efforts in CNS beyond degenerative nerve diseases into psychiatric diseases.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts